Literature DB >> 24600127

JAK2 V617F negative essential thrombocythemia.

A W Kashif1, Sameer Aggarwal2, Tarun Verma3, R M Gupta4.   

Abstract

Entities:  

Keywords:  Erythromelalgia; Essential thrombocythemia; JAK 2 V 617 kinase; Myeloproliferative neoplasm

Year:  2012        PMID： 24600127      PMCID： PMC3862892          DOI： 10.1016/j.mjafi.2012.09.006

Source DB:  PubMed          Journal:  Med J Armed Forces India        ISSN： 0377-1237


× No keyword cloud information.
  7 in total

Review 1.  Guideline for investigation and management of adults and children presenting with a thrombocytosis.

Authors:  Claire N Harrison; David Bareford; Nauman Butt; Peter Campbell; Eibhlean Conneally; Mark Drummond; Wendy Erber; Tamara Everington; Anthony R Green; Georgina W Hall; Beverley J Hunt; Christopher A Ludlam; Richard Murrin; Catherine Nelson-Piercy; Deepti H Radia; John T Reilly; Jon Van der Walt; Bridget Wilkins; Mary F McMullin
Journal:  Br J Haematol       Date:  2010-03-15       Impact factor: 6.998

2.  Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status.

Authors:  Alessandra Carobbio; Guido Finazzi; Vittoria Guerini; Orietta Spinelli; Federica Delaini; Roberto Marchioli; Giovanna Borrelli; Alessandro Rambaldi; Tiziano Barbui
Journal:  Blood       Date:  2006-11-16       Impact factor: 22.113

Review 3.  Essential thrombocythemia: a review of diagnostic and pathologic features.

Authors:  Steven Sanchez; April Ewton
Journal:  Arch Pathol Lab Med       Date:  2006-08       Impact factor: 5.534

4.  Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area.

Authors:  M K Jensen; P de Nully Brown; O J Nielsen; H C Hasselbalch
Journal:  Eur J Haematol       Date:  2000-08       Impact factor: 2.997

5.  Erythromelalgia as a presenting manifestation in a patient with essential thrombocythemia complicating renovascular hypertension due to unilateral renal artery stenosis.

Authors:  Jin-Wuk Hur; Young-Yiul Lee; Woong-Soo Lee; Jae-Bum Jun
Journal:  Rheumatol Int       Date:  2005-03-05       Impact factor: 2.631

Review 6.  Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders.

Authors:  Ross L Levine; Animesh Pardanani; Ayalew Tefferi; D Gary Gilliland
Journal:  Nat Rev Cancer       Date:  2007-09       Impact factor: 60.716

7.  Cutaneous manifestations in patients with essential thrombocythemia.

Authors:  P H Itin; R K Winkelmann
Journal:  J Am Acad Dermatol       Date:  1991-01       Impact factor: 11.527
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.